The therapeutic landscape for treating relapsed/refractory chronic lymphocytic
leukemia (R/R CLL) is rapidly evolving, with numerous trials and approvals leading
to the availability of multiple treatment options. Though this range of therapies
enables the individualization of treatment for patients, it also creates a need
to establish optimal treatment sequencing.
In this live virtual event, experts will review the current treatment guidelines
for R/R CLL and the latest data and approvals. They will discuss the best practices
for treating patients, which factors to consider when selecting a treatment, and how
to incorporate the latest approvals to ensure patients receive the best available
therapy. They will also look ahead to the upcoming European Hematology Association
(EHA) 2024 congress, and comment on the most promising abstracts to be presented at the meeting.
Join this essential webinar on targeted therapies for R/R CLL developed by Medscape Global
Oncology and the Lymphoma Coalition.
Clinical Director of Lymphoma
Fred Hutchinson Cancer Center
Clinical Professor of Medicine
University of Washington
Washington, United States
University of Cologne
Faculty of Medicine and University Hospital Cologne
Department I of Internal Medicine
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf
Cologne, Germany
Upon completion of this activity, learners will be able to:
- Define the latest clinical safety/efficacy evidence in R/R CLL
- Assess how to integrate the latest evidence in R/R CLL to optimize long-term benefit
- Incorporate new data to further individualize treatment for R/R CLL
The goal of this activity is for learners to be better able to define the current treatment algorithm of R/R CLL and the potential impact of key clinical data to individualize future management.
This activity is intended for hematology/oncology specialists and other members of the oncology multidisciplinary team (excluding the UK).
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 0.75 contact hour(s) (0. 75 CEUs) (Universal Activity Number: JA0007105-0000-24-114-L01-P).
Supported by an educational grant from Lilly.
Developed through the strategic collaboration between